1. Home
  2. AGIO vs RVLV Comparison

AGIO vs RVLV Comparison

Compare AGIO & RVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.43

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Revolve Group Inc.

RVLV

Revolve Group Inc.

HOLD

Current Price

$25.10

Market Cap

1.8B

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
RVLV
Founded
2007
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Catalog/Specialty Distribution
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
AGIO
RVLV
Price
$27.43
$25.10
Analyst Decision
Buy
Buy
Analyst Count
8
13
Target Price
$37.63
$29.75
AVG Volume (30 Days)
791.9K
1.4M
Earning Date
05-15-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
24.64
EPS
N/A
0.86
Revenue
$43,011,000.00
$1,225,682,000.00
Revenue This Year
$75.68
$10.96
Revenue Next Year
$167.63
$8.01
P/E Ratio
N/A
$29.66
Revenue Growth
N/A
8.48
52 Week Low
$22.24
$16.80
52 Week High
$46.00
$31.68

Technical Indicators

Market Signals
Indicator
AGIO
RVLV
Relative Strength Index (RSI) 42.16 45.66
Support Level $26.40 $20.34
Resistance Level $29.49 $26.65
Average True Range (ATR) 1.18 1.32
MACD -0.19 0.13
Stochastic Oscillator 14.64 65.78

Price Performance

Historical Comparison
AGIO
RVLV

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About RVLV Revolve Group Inc.

Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.

Share on Social Networks: